Physician profile
Naveed Iqbal
NPI 1558337675
$27,488.66
in general payments reported to CMS, 2019-2025
19 companies · $7,975 in 2025
The $7,975 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,965 · 2020: $57.25 · 2021: $220 · 2022: $470 · 2023: $719 · 2024: $14K · 2025: $7,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,600 · Food and Beverage: $1,834 · Travel and Lodging: $875 · Education: $58.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,410.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,600.00 |
| Food and Beverage | $1,833.59 |
| Travel and Lodging | $874.80 |
| Education | $58.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21,551.36 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $3,510.74 | 2019-2022 | |
| Abbvie INC. | $1,001.62 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $266.51 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $258.30 | 2019-2023 | Uzedy |
| Janssen Pharmaceuticals, INC | $208.91 | 2019-2020 | |
| Axsome Therapeutics, INC. | $183.27 | 2024-2025 | Auvelity, Sunosi |
| Neuronetics, INC. | $100.19 | 2019-2020 | |
| Indivior INC. | $67.53 | 2022-2023 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $67.25 | 2019-2024 | Trintellix |
| Almatica Pharma LLC | $53.13 | 2021-2022 | |
| Alkermes, INC. | $43.43 | 2021-2024 | Lybalvi |
| Avanir Pharmaceuticals, INC. | $36.72 | 2019 | |
| Bausch Health US, LLC | $34.85 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $30.06 | 2024 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $26.41 | 2019 | |
| Merck Sharp & Dohme LLC | $16.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.83 | 2019 | |
| Lundbeck LLC | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.